Effects of metrifonate on cognitive decline in Alzheimer disease: A double-blind, placebo-controlled, 6-month study
Effects of metrifonate on cognitive decline in Alzheimer disease: A double-blind, placebo-controlled, 6-month study
复制标题
DOI：
10.1097/00002093-199803000-00009
复制
发表时间：
1998-03-01
影响因子：
2.1
通讯作者：
Vicari, S
中科院分区：
文献类型：
--
作者：
Becker, RE;Colliver, JA;Vicari, S
47名可能患有阿尔茨海默病（AD）的患者完成了一项为期6个月的双盲研究，将三氟膦酸钠与安慰剂进行比较。在阿尔茨海默病评估量表认知亚量表评分中，由于安慰剂组的认知表现恶化（p < 0.01），三氟化钠组的红细胞乙酰胆碱酯酶活性抑制率为50-70%，与安慰剂组的评分差异显著，差异为1.8分（p < 0.03）。安慰剂治疗组的精神状态检查评分也有统计学意义的下降（p < 0.01）。不良反应不常见，不需要调整剂量或停止治疗。这些发现扩展了我们之前关于三氟膦酸盐对阿尔茨海默病认知症状有利作用的报道，显示了临床意义，而不仅仅是统计学意义。
Forty-seven patients with probable Alzheimer disease (AD) completed a 6 month double-blind study to compare metrifonate with placebo. The Alzheimer Disease Assessment Scale cognitive subscale score of the metrifonate group treated to a 50-70% inhibition of red blood cell acetylcholinesterase activity differed significantly from the placebo group score by 1.8 points (p < 0.03) due to a deterioration in cognitive performance in the placebo group (p < 0.01). Statistically significant deterioration also occurred in the Mini-Mental State Examination scores (p < 0.01) in the placebo-treated group. Adverse effects were uncommon and did not require adjustment of the dose of metrifonate or discontinuation of treatment. These findings extend our previous report of a favorable effect of metrifonate on cognitive symptoms in AD by showing clinical, not only statistical, significance.